๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease

โœ Scribed by Charles Z. Ding; Yong-Kang Zhang; Xianfeng Li; Yang Liu; Suoming Zhang; Yasheen Zhou; Jacob J. Plattner; Stephen J. Baker; Liang Liu; Maosheng Duan; Richard L. Jarvest; Jingjing Ji; Wieslaw M. Kazmierski; Matthew D. Tallant; Lois L. Wright; Gary K. Smith; Renae M. Crosby; Amy A. Wang; Zhi-Jie Ni; Wuxin Zou; Jon Wright


Book ID
104005030
Publisher
Elsevier Science
Year
2010
Tongue
English
Weight
663 KB
Volume
20
Category
Article
ISSN
0960-894X

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Synthesis of new acylsulfamoyl benzoxabo
โœ Xianfeng Li; Yong-Kang Zhang; Yang Liu; Suoming Zhang; Charles Z. Ding; Yasheen ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 668 KB

HCV NS3/4A serine protease is essential for the replication of the HCV virus and has been a clinically validated target. A series of HCV NS3/4A protease inhibitors containing a novel acylsulfamoyl benzoxaborole moiety at the P1' region was synthesized and evaluated. The resulting P1-P3 and P2-P4 mac

Design and synthesis of novel fluoro ami
โœ Latha G. Nair; Stephane Bogen; Frank Bennett; Kevin Chen; Bancha Vibulbhan; Yuhu ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› Elsevier Science ๐ŸŒ French โš– 952 KB

The Hepatitis C Virus (HCV) is a major health hazard and its infection is a leading cause of chronic liver disease world wide. In our efforts toward the discovery of a back up to our first clinical candidate, Boceprevir (SCH 503034), we approached the depeptidization of the molecule through macrocyc